Prasugrel 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone CAS NO.150322-43-3

We can provide Prasugrel base and related several intermediates of this series with high quality and competitive price and service.

Appearance: White to off-white powder

Purity: NLT99.0%

[Product Info]

Product Name: Prasugrel

CAS No.: 150322-43-3

Molecular Formula: C20H20FNO3S

Molecular Weight: 373.44

Appearance: White to off-white powder

Purity: NLT99.0%

Packing: 1Kg/package, 5Kg/pacakge, or according to customer's requirements.

Storage: Sealed and preserved from light.

Antiplatelet drugs []

Prasugrel is by Eli Lilly and Japanese drugmaker Daiichi Sankyo company (DaiichiSankyo) development of thienopyridine antiplatelet drug, is a pro drug, in the liverby cytochrome P450 metabolism after the formation of active molecules, bindingand platelet P2Y12 receptor and exert antiplatelet aggregation activity. Clinical studies demonstrate that, compared with the 60 mg dose clopidogrel 300 mg and 600 mg of standard dose increased dose has better anti clotting effect, can make the patient of heart attack, stroke, heart disease deaths due to comprehensive riskis reduced by 20%, and quick effect, good curative effect, use drug resistance andgood bioavailability, toxicity is low.

Prasugrel in stable angina and acute coronary syndrome interventional operation is also stronger than clopidogrel antiplatelet effect is more strong, but also more easily cause bleeding. The key question now is how we identify thrombosis risk in clinical patients, and how to identify the risk of hemorrhage of high-risk groups,which can make the difference between Prager Ray and clopidogrel use in twohigh-risk groups, both to reduce coronary thrombosis and avoid major bleeding.

In December 18, 2008, prasugrel obtained its first major international accreditation,the European Medicines Agency Europeans for Medical Products Committee(CHMP) to recommend approval of the drug.

In late February 2009 by the European Commission's permission. In Europe, sold under the brand name Efient, used in the treatment of acute coronary syndrome.The working principle of prasugrel is adopted in the platelet surface prevents P2Y12 adenosine two phosphate receptor and inhibit platelet activation andaggregation of concurrent. Antiplatelet drugs used to prevent platelet aggregationor glued together, if platelet aggregation can lead to clogged arteries and maycause a heart attack or stroke.

In July 10, 2009 American approved by the food and drug administration receivedprasugrel tablets for angioplasty patients, in order to reduce the risk of blood clots.

In 2010 April in Canada approved, for the treatment of acute coronary syndrome.

Prasugrel tag has boxed warnings, remind the doctor the drug may cause the obvious, sometimes fatal bleeding. This product should not be used for the following patients: current pathological hemorrhage; a history of stroke or transient ischemic attack; or the need for emergency operation, including coronary artery bypass operation.